Velban, Vinblastine Newswire

Velban, Vinblastine Newswire

Comprehensive Real-Time News Feed for Velban, Vinblastine (generic).

Results 1 - 20 of 43 in Velban, Vinblastine (generic)

  1. North America Prostate Cancer Market estimated to be growing at a...Read the original story

    Friday Jul 21 | Emailwire.com

    North America Prostate Cancer Market estimated to be growing at a CAGR of 8.97%, to reach $25.08 billion by 2021. North America Prostate Cancer Market by Diagnostic Techniques and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts According to the report North America Prostate Cancer published by Market Data Forecast, the North American market was worth $16.32 billion in 2016 and is projected to reach $25.08 billion with CAGR of 8.97% by 2021 Prostate Cancer Market is one of the serious health issues among men that have large socioeconomic impact on the society.

    Comment?

  2. Real-life clinical practice results with vinflunine in patients with...Read the original story w/Photo

    Tuesday Jul 18 | BioMed Central

    Vinflunine is the only chemotherapeutic agent shown to improve survival in platinum-refractory patients with metastatic transitional cell carcinoma of the urothelium in a phase III clinical trial, which led to product registration for this indication in Europe. The aim of this study was to assess the efficacy of vinflunine and to evaluate the prognostic significance of risk factors in a large, unselected cohort of patients with metastatic TCCU treated according to routine clinical practice.

    Comment?

  3. Urothelial Carcinoma Treatment Market to Experience Hike in Growth by 2024Read the original story w/Photo

    Wednesday Jul 19 | SBWire

    Urothelial carcinoma is a malignant neoplasm resulting from transitional epithelium, occurring mainly in the urinary bladder, renal pelves or ureters; frequently papillary. These carcinomas are classified according to the degree of anaplasia.

    Comment?

  4. Lowe makes FDA breakthroughRead the original story w/Photo

    Wednesday Jul 12 | Jamaica Observer

    A drug developed from cannabis by Jamaican scientist Dr Henry Lowe and his team of researchers to treat acute myeloid leukaemia has been granted orphan-drug designation by the United States Food and Drug Administration . Dr Lowe, who described the development as historic, pointed out that the FDA designation could see the drug, which has the trade name Cresorol, being placed on the market within three years, with estimated annual minimum sales of more than US$250 million in the US market alone.

    Comment?

  5. Why Shares of Seattle Genetics, Inc. Got Whacked TodayRead the original story w/Photo

    Monday Jun 26 | Fox News

    You read that right: Shares are down on positive clinical trial results. Unfortunately, in biotech, sometimes it's the magnitude of the win that counts.

    Comment?

  6. Takeda and Seattle Genetics Announce Positive Results from Phase 3...Read the original story

    Monday Jun 26 | Information Technology

    Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS in Frontline Advanced Hodgkin Lymphoma Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc. today announced that the Phase 3 ECHELON-1 clinical trial met its primary endpoint of a statistically significant improvement in modified progression-free survival versus the control arm. ECHELON-1 is a randomized, multicenter trial evaluating ADCETRIS as part of a frontline combination chemotherapy regimen in 1,334 patients with previously untreated advanced classical Hodgkin lymphoma.

    Comment?

  7. Investors Relieved as Seattle Genetics Pulls Out Win for Phase III Lymphoma TrialRead the original story

    Sunday Jun 25 | BioSpace

    Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRISA in Frontline Advanced Hodgkin Lymphoma -Randomized Phase 3 Clinical Trial with ADCETRIS Met Primary Endpoint, Demonstrating a Statistically Significant Improvement in Modified Progression-Free Survival- today announced that the Phase 3 ECHELON-1 clinical trial met its primary endpoint of a statistically significant improvement in modified progression-free survival versus the control arm. ECHELON-1 is a randomized, multicenter trial evaluating ADCETRIS as part of a frontline combination chemotherapy regimen in 1,334 patients with previously untreated advanced classical Hodgkin lymphoma.

    Comment?

  8. Single Agent Chemotherapy Market Research Report: Market Competition, ...Read the original story w/Photo

    May 18, 2017 | SBWire

    Single agent chemotherapy refers to the treatment of cancer with a potent single chemotherapy drug instead of multiple chemotherapy agents. Though, the combination chemotherapy is standard treatment method in most of cancer cases, increasing burden of high risk side effects and adverse effects of combination therapy has promoted use of single agent in management of cancer.

    Comment?

  9. Plant report reveals new discoveries, climate survivorsRead the original story w/Photo

    May 18, 2017 | Reuters

    The second annual ''State of the World's Plants'' report, involving 128 scientists, examines the winners and losers in the plant world under a changing climate. Matthew Stock reports.

    Comment?

  10. Top 3 Trends Impacting the Global Kaposi Sarcoma Market Through 2021: TechnavioRead the original story w/Photo

    May 16, 2017 | Business Wire

    Sapna Jha, a lead analyst from Technavio, specializing in research on oncology s ector, says , "The global Kaposi sarcoma market is expected to benefit from rising AIDS/HIV incidence across the globe. The condition seems to be more serious in the African region as this region has the largest number of HIV-positive population.

    Comment?

  11. Urothelial Carcinoma Treatment Market Global Industry Volume by Region 2016 - 2024Read the original story w/Photo

    May 12, 2017 | SBWire

    Urothelial carcinoma is a malignant neoplasm resulting from transitional epithelium, occurring mainly in the urinary bladder, renal pelves or ureters; frequently papillary. These carcinomas are classified according to the degree of anaplasia.

    Comment?

  12. Urothelial Carcinoma Treatment Market - Global Industry Volume and Region Analysis - 2024Read the original story w/Photo

    May 11, 2017 | PR-inside.com

    Transparency Market Research Report Added "Urothelial Carcinoma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024" Urothelial carcinoma is a malignant neoplasm resulting from transitional epithelium, occurring mainly in the urinary bladder, renal pelves or ureters; frequently papillary. These carcinomas are classified according to the degree of anaplasia.

    Comment?

  13. Asia-Pacific Prostate Cancer Market Research Analysis report 2021Read the original story

    Apr 25, 2017 | Emailwire.com

    According to the report 'Asia-Pacific Prostate Cancer Market' published by Market Data Forecast, the Asia-Pacific market was worth $8.64 billion in 2016 and is projected to reach $14.33 billion with CAGR of 10.65% by 2021 According to the report Asia-Pacific Prostate Cancer Market published by Market Data Forecast, the Asia-Pacific market was worth $8.64 billion in 2016 and is projected to reach $14.33 billion with CAGR of 10.65% by 2021 For full report refer to ' ' Prostate cancer is a progression of cancer in the prostate, a gland present in the male reproductive system. The cancer cells might reach to the other parts of the body, viz.

    Comment?

  14. Anticholangiocarcinoma activity and toxicity of the Kaempferia...Read the original story w/Photo

    Apr 11, 2017 | BioMed Central

    Cholangiocarcinoma is an important public health problem in several tropical and subtropical parts of the world particularly Thailand. Chemotherapy of CCA is largely ineffective and discovery and development of effective alternative drugs is urgently needed.

    Comment?

  15. Decreased levels of baseline and drug-induced tubulin polymerisation...Read the original story

    Apr 11, 2017 | British Journal of Cancer

    ABCB1 expression is uncommon in ovarian cancers in the clinical setting so we investigated non-MDR mechanisms of resistance to taxanes. 1A9, ES-2, MES-OV and OVCAR-3 by selection with paclitaxel or docetaxel, with counter-selection by the transport inhibitor valspodar.

    Comment?

  16. OSU scientists find way to fight solid tumors using new cancer-drug delivery systemRead the original story w/Photo

    Apr 4, 2017 | Medical News

    A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiation treatment. Carcinomas that affect the breast, lung, prostate and colon are among these solid-tumor cancers, as are malignancies in the lymphatic system, known as lymphomas, and the much less common sarcomas that arise in connective tissue.

    Comment?

  17. New drug delivery system could help fight tumorsRead the original story w/Photo

    Apr 4, 2017 | UPI

    Researchers at Oregon State University have developed a new cancer-drug delivery system that may help overcome the challenge of treating solid tumors often resistant to treatment. Carcinomas, a type of cancer that affect the lung, prostate, colon and breast, are solid tumors that contain hypoxic or low oxygen regions that cause slow growth and resistance to drug treatment to shrink or kill the tumor.

    Comment?

  18. New drug delivery system shows promise for fighting solid tumorsRead the original story w/Photo

    Apr 4, 2017 | PhysOrg Weblog

    A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiation treatment. Carcinomas that affect the breast, lung, prostate and colon are among these solid-tumor cancers, as are malignancies in the lymphatic system, known as lymphomas, and the much less common sarcomas that arise in connective tissue.

    Comment?

  19. Catharanthine Market Value Chain and Forecast 2016-2026Read the original story w/Photo

    Apr 2, 2017 | PR-inside.com

    Future Market Insights has announced the addition of the "Catharanthine Market: Global Industry Analysis and Opportunity Assessment 2016-2026" report to their offering. Medicinal plants today form a major portion of rich biodiversity globally and are still not explored to its potential.

    Comment?

  20. Dr. Morag Park Won Prestigious AwardRead the original story w/Photo

    Mar 9, 2017 | McGill University

    Dr Morag Park, an associate member and research director for two of our PhD candidates in the department of Pathology, is the recipient of the Canadian Cancer Society 2017 Robert L. Noble Prize, as announced on March 8. An acclaimed leader in Canadian cancer research, Dr. Park is widely recognized for her outstanding work in identifying key events in cancer development and the importance of tumour surroundings for cancer growth. She has also demonstrated exceptional leadership in establishing national cancer research strategies as acknowledged by the Canadian Cancer Society.

    Comment?